ATHERSYS, INC 8-K 2016
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 12, 2016
(Exact Name of Registrant as Specified in Charter)
Registrants telephone number, including area code: (216) 431-9900
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On September 12, 2016, Athersys, Inc. (Athersys) announced the authorization the commencement by its collaborator, HEALIOS K.K., of a clinical trial in Japan evaluating the safety and efficacy of administration of MultiStem® cell therapy, Athersys novel stem cell therapy, to treat patients who have suffered an ischemic stroke. A copy of the press release issued by Athersys announcing the clinical trial is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 12, 2016